Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification

Am J Cardiol. 2021 Dec 1:160:46-52. doi: 10.1016/j.amjcard.2021.08.042. Epub 2021 Sep 25.

Abstract

Atrial fibrillation (AF) is the most common clinically significant arrhythmia, and it increases stroke risk. A preventive approach to AF is needed because virtually all treatments such as cardioversion, antiarrhythmic drugs, ablation, and anticoagulation are associated with high cost and carry significant risk. A systematic review was performed to identify effective lifestyle-based strategies for reducing primary and secondary AF. A PubMed search was performed using articles up to March 1, 2021. Search terms included atrial fibrillation, atrial flutter, exercise, diet, metabolic syndrome, type 2 diabetes mellitus, obesity, hypertension, stress, tobacco smoking, alcohol, Mediterranean diet, sodium, and omega-3 fatty acids. Additional articles were identified from the bibliographies of retrieved articles. The control of hypertension, ideally with a renin-angiotensin-aldosterone system inhibitor, is effective for preventing primary AF and recurrence. Obstructive sleep apnea is a common cause of AF, and treating it effectively reduces AF episodes. Alcohol increases the risk of AF in a dose-dependent manner, and abstinence reduces risk of recurrence. Sedentary behavior and chronic high-intensity endurance exercise are both risk factors for AF; however, moderate physical activity is associated with lower risk of AF. Recently, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 agonists have been associated with reduced risk of AF. Among overweight/obese patients, weight loss of ≥10% is associated with reduced AF risk. Lifestyle changes and risk factor modification are highly effective for preventing AF.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Alcohol Drinking / epidemiology
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / prevention & control*
  • Atrial Fibrillation / therapy
  • Bariatric Surgery
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / therapy
  • Diet Therapy*
  • Diet, Mediterranean
  • Dietary Fats, Unsaturated
  • Endurance Training
  • Exercise*
  • Fatty Acids, Omega-3
  • Glucagon-Like Peptide 1 / agonists
  • Humans
  • Metabolic Syndrome / epidemiology
  • Metabolic Syndrome / therapy
  • Obesity / epidemiology
  • Obesity / therapy
  • Overweight / epidemiology
  • Overweight / therapy
  • Risk Reduction Behavior*
  • Sedentary Behavior
  • Sleep Apnea, Obstructive / epidemiology
  • Sleep Apnea, Obstructive / therapy
  • Smoking / epidemiology
  • Smoking / therapy
  • Smoking Cessation*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Weight Loss

Substances

  • Dietary Fats, Unsaturated
  • Fatty Acids, Omega-3
  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucagon-Like Peptide 1